Phase II Clinical Trial of CD34+ Cell Therapy to Explore Endpoint Selection and Timing in Patients With Critical Limb IschemiaYasuyuki Fujita, Atsuhiko Kawamoto, Makoto Kinoshita et al.|Circulation Journal|2013Cited by 70
Intravenous Injection of Muse Cells as a Potential Therapeutic Approach for Epidermolysis BullosaYasuyuki Fujita, Hiroshi Shimizu, Shota Takashima et al.|Journal of Investigative Dermatology|2020Cited by 37
Honedra® (CLBS12) autologous CD34+ cells improve outcomes in patients with Buerger’s diseaseAtsuhiko Kawamoto, Douglas W. Losordo, Yutaka Furukawa et al.|Cytotherapy|2021Cited by 0